Notes
Slide Show
Outline
1
Endocrine Emergency Pharmacology
2
Diabetes Mellitus
3
Diabetes Mellitus
  • A hormone is a chemical substance produced by an organ or specialized cells that regulates or controls the activities of another organ.
  • The pancreas is located in the retroperitoneal space, within the folds of the small intestine.
4
Diabetes Mellitus (cont.)
  • Within the pancreas is an area called the islets of Langerhans.
  • The islets secretes three hormones:
    • The α cells secrete the hormone glucagon.
    • The β cells secrete insulin.
    • The δ cells secrete somatostatin.
5
Diabetes Mellitus (cont.)
  • Insulin is required for the passage of glucose into the cells.
  • Glucagon causes stored carbohydrates to be broken down to glucose.
  • Diabetes mellitus is caused when β cells of the pancreas reduce the amount of insulin secreted.
6
Diabetes Mellitus (cont.)
  • Type I diabetes mellitus
    • Possibly caused by a viral infection that attacks the pancreatic β cells
    • Possibly caused by the immune system targeting the pancreatic β cells
    • Heredity is a factor
    • Patient must take a daily dose of insulin
7
Diabetes Mellitus (cont.)
  • Type II diabetes mellitus
    • Occurs more commonly than type I
    • Usually begins later in life
    • Pancreas is less responsive to stimulation from increased blood glucose levels
    • Usually does not require insulin injections
    • Does not usually result in DKA
    • Can develop nonketotic hyperosmolar coma
8
Diabetes Mellitus (cont.)
  • Diabetic ketoacidosis
    • Insulin levels decrease
    • Blood glucose levels increase
    • Individual cells become glucose-depleted
    • Ketones and acids are produced
    • Metabolic acidosis insues
    • Left uncorrected, coma will follow
9
Diabetes Mellitus (cont.)
  • Hypoglycemia
    • Commonly referred to as “insulin shock”
    • Usually has a rapid onset
    • Insulin levels increase
    • Blood glucose levels decrease
    • Lack of glucose will cause brain injury


10
Insulin
  • Humulin, Novolin, Iletin
11
Class
  • Hormone and antihyperglycemic
12
Description
  • In diabetics incapable of producing an adequate amount of insulin, supplemental insulin must be obtained by injection.
  • Many patients develop antibodies to animal insulin, rendering it less effective.
  • Genetically engineered insulin (Humulin, Novolin) is chemically identical to the insulin hormone secreted by the pancreas.
13
Mechanism of Action
  • Combines with insulin receptors present on the cell membranes
  • Promotes glucose entry into the cell
  • Lowers the blood glucose level
14
Pharmacokinetics
  • Onset
    • 30-60 minutes
  • Peak effects
    • 2-3 hours
  • Duration
    • 5-7 minutes
  • Half-life
    • 13 hours
15
Indications
  • Diabetic ketoacidosis
  • Hyperglycemia
  • Hyperkalemia
16
Contraindications
  • Should be administered only when hyperglycemia or ketoacidosis has been confirmed
  • Blood glucose approximation should be obtained in all diabetic emergencies
  • Usually not used during the prehospital phase of emergency medical care
17
Precautions
  • Repeated measurements of the blood glucose level, including possible administration of glucose, are necessary.
18
Side Effects
  • Hypoglycemia
  • Itching
  • Swelling
  • Redness
  • Allergic reactions may occur following administration of animal-derived insulins.
19
Interactions
  • Corticosteroids can increase the blood glucose level.
  • Patients receiving these drugs may require a higher dose of insulin.
  • Signs and symptoms of hypoglycemia may be masked in patients receiving β-blockers.
20
Dosage
  • Dose for diabetic coma is 5-10 units of regular insulin IV
  • Followed by an infusion at 0.1 unit/kg per hour
  • 5-20 units of regular insulin SC/IM if there is not an immediate need for IV insulin
21
Glucagon
22
Class
  • Hormone and antihypoglycemic
23
Description
  • A protein secreted by the α cells of the pancreas
  • Used to increase the blood glucose level in cases of hypoglycemia in which an IV cannot be immediately obtained
24
Mechanism of Action
  • When released, causes a breakdown of stored glycogen to glucose
  • Also inhibits the synthesis of glycogen from glucose
  • Both actions tend to cause an increase in circulating blood glucose.
25
Pharmacokinetics
  • Onset
    • 5-20 minutes
  • Peak effects
    • 30 minutes
  • Duration
    • 1-2 hours
  • Half-life
    • N/A
26
Indications
  • Hypoglycemia
  • β-blocker overdose
27
Contraindications
  • Glucagon is a protein, so hypersensitivity may occur.
  • Known hypersensitivity to the drug
28
Precautions
  • Only effective if there are sufficient stores of glycogen within the liver
  • Drug of choice in the management of insulin-induced hypoglycemia is D50W
  • Should be administered with caution to patients with a history of cardiovascular or renal disease
29
Side Effects
  • Hypotension
  • Dizziness
  • Headache
  • Nausea and vomiting
30
Interactions
  • Few interactions in the emergency setting
31
Dosage
  • Standard initial dose is 0.25-0.5 units IVP
  • If no IV, 1 mg IM
  • Can be administered IV, IM, or SC
32
50% Dextrose in Water
  • D50W
33
Class
  • Carbohydrate
34
Description
  • Dextrose is used to describe the six-carbon sugar d-glucose.
  • Principal form of carbohydrate used by the body
35
Mechanism of Action
  • Dextrose supplies supplemental glucose in cases of hypoglycemia.
  • Serious brain injury can occur if hypoglycemia is prolonged.
36
Pharmacokinetics
  • Onset
    • < 1 minute
  • Peak effects
    • Variable
  • Duration
    • Variable
  • Half-life
    • N/A
37
Indications
  • Hypoglycemia
  • Coma of unknown origin
38
Contraindications
  • No major contraindications to the IV administration of D50W to a patient with suspected hypoglycemia
  • Should be used with caution in patients with increased intracranial pressure because the dextrose load may worsen cerebral edema
39
Precautions
  • Obtain a Glucometer reading and draw a sample of blood before giving D50W.
  • Therapy should always be guided by objective data such as patient assessment findings and blood glucose determination.
  • Extravasation may occur when smaller veins are used.
40
Side Effects
  • Tissue necrosis and phlebitis at the injection site
41
Interactions
  • None in the emergency setting
42
Dosage
  • Standard dosage in hypoglycemia is 25 g (50 mL of a 50% solution) IVP
  • A second dose of 25 g, if first dose is ineffective
  • Pediatrics
    • Dilute 1:1 with sterile water forming D25W
    • The dose is 0.5-1.0 g/kg slow IVP
43
Thiamine
44
Class
  • Vitamin
45
Description
  • An important vitamin commonly referred to as vitamin B1
  • Required for the conversion of pyruvic acid to acetyl coenzyme A
46
Mechanism of Action
  • A vitamin is a substance that the body cannot manufacture but that is required for metabolism.
  • Without thiamine, a significant amount of the energy available in glucose cannot be obtained.
  • Chronic alcohol intake interferes with the absorption, intake, and use of thiamine.
47
Mechanism of Action (cont.)
  • The brain is extremely sensitive to thiamine deficiency.
  • Wernicke’s encephalopathy
    • Acute and reversible encephalopathy
    • Characterized by an unsteady gait, eye muscle weakness, and mental derangement
  • Korsakoff’s psychosis is a significant memory disorder and may be irreversible.
48
Pharmacokinetics
  • Onset
    • Rapid
  • Peak effects
    • Variable
  • Duration
    • Variable
  • Half-life
    • N/A
49
Indications
  • Coma of unknown origin, especially if alcohol may be involved
  • Delirium tremens
50
Contraindications
  • None in the emergency setting
51
Precautions
  • A few cases of hypersensitivity to thiamine have been reported.
  • Therapy should always be guided by objective data such as patient assessment findings and blood glucose determination.
52
Side Effects
  • Few side effects reported
  • Rare reports of:
    • Hypotension
    • Dyspnea
    • Respiratory failure

53
Interactions
  • None in the emergency setting
54
Dosage
  • 100 mg IVP or IM